Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...

Interim results demonstrated PLN-101095 anti-tumor activity in combination with pembrolizumab, with three partial responses observed in cohort three at the 1000 mg administered orally twice daily ...

(RTTNews) - Pliant Therapeutics, Inc. (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

PLN-101095, an oral small molecule inhibitor targeting integrins αvβ8 and αvβ1, is designed to prevent the activation of transforming growth factor-β, which contributes to the immune ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder ...

Pliant is conducting a Phase 1 study of PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors.